

University of Dundee

## A role for trypanosomatid aldo-keto reductases in methylglyoxal, prostaglandin and isoprostane metabolism

Roberts, Adam; Dunne, Joanne; Scullion, Stanley; Norval, Suzanne; Fairlamb, Alan

*Published in:*  
Biochemical Journal

*DOI:*  
[10.1042/BCJ20180232](https://doi.org/10.1042/BCJ20180232)

*Publication date:*  
2018

*Licence:*  
CC BY

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

### *Citation for published version (APA):*

Roberts, A., Dunne, J., Scullion, S., Norval, S., & Fairlamb, A. (2018). A role for trypanosomatid aldo-keto reductases in methylglyoxal, prostaglandin and isoprostane metabolism. *Biochemical Journal*, 475(16), 2593-2610. <https://doi.org/10.1042/BCJ20180232>

### **General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Research Article

# A role for trypanosomatid aldo-keto reductases in methylglyoxal, prostaglandin and isoprostane metabolism

Adam J. Roberts\*, Joanne Dunne<sup>†</sup>, Paul Scullion, Suzanne Norval and  Alan H. Fairlamb

Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

**Correspondence:** Alan H. Fairlamb (a.h.fairlamb@dundee.ac.uk)



Trypanosomatid parasites are the infectious agents causing Chagas disease, visceral and cutaneous leishmaniasis and human African trypanosomiasis. Recent work of others has implicated an aldo-keto reductase (AKR) in the susceptibility and resistance of *Trypanosoma cruzi* to benznidazole, a drug used to treat Chagas disease. Here, we show that *TcAKR* and homologues in the related parasites *Trypanosoma brucei* and *Leishmania donovani* do not reductively activate monocyclic (benznidazole, nifurtimox and fexinidazole) or bicyclic nitro-drugs such as PA-824. Rather, these enzymes metabolise a variety of toxic ketoaldehydes, such as glyoxal and methylglyoxal, suggesting a role in cellular defence against chemical stress. UPLC-QToF/MS analysis of benznidazole bioactivation by *T. cruzi* cell lysates confirms previous reports identifying numerous drug metabolites, including a dihydro-dihydroxy intermediate that can dissociate to form *N*-benzyl-2-guanidinoacetamide and glyoxal, a toxic DNA-glycating and cross-linking agent. Thus, we propose that *TcAKR* contributes to benznidazole resistance by the removal of toxic glyoxal. In addition, three of the four enzymes studied here display activity as prostaglandin  $F_{2\alpha}$  synthases, despite the fact that there are no credible cyclooxygenases in these parasites to account for formation of the precursor  $PGH_2$  from arachidonic acid. Our studies suggest that arachidonic acid is first converted non-enzymatically in parasite lysates to ( $PGH_2$ -like) regioisomers by free radical-mediated peroxidation and that AKRs convert these lipid peroxides into isoprostanes, including prostaglandin  $F_{2\alpha}$  and 8-iso-prostaglandin  $F_{2\alpha}$ .

## Introduction

Parasitic protozoa belonging to the order Kinetoplastida cause three neglected tropical diseases, Chagas disease, human African trypanosomiasis and leishmaniasis due to infection with *Trypanosoma cruzi*, *Trypanosoma brucei* and *Leishmania* spp., respectively, see review [1]. The burden of these three ‘neglected’ tropical diseases is almost exclusively associated with poverty and therefore there has been little incentive for pharmaceutical companies to invest in developing new treatments, see review [2]. Currently, the nitro-drugs benznidazole and nifurtimox developed over 40 years ago are the only therapies available for the treatment of Chagas disease, with nifurtimox also constituting part of the combination therapy ‘NECT’ for late-stage human African trypanosomiasis [3]. In addition, another nitro-drug, fexinidazole, has shown activity against all three parasites [4–6] and consequentially is now under clinical assessment for all three diseases.

The anti-parasitic activities of these nitro-containing pro-drugs are dependent upon parasite-facilitated bio-activation by a bacterial-like type I nitroreductase NTR1 [7] to form toxic reactive intermediates [8–10], and consequently, loss of NTR1 is a key resistance determinant [11,12]. Notably, other enzymes have been implicated in resistance to benznidazole in *T. cruzi*, the FMN containing ‘old yellow enzyme’ a functional prostaglandin  $F_{2\alpha}$  synthase [13,14] and an aldo-keto reductase (AKR)

\*Present address: Cell Surface Signalling Laboratory, Wellcome Trust Sanger Institute, Cambridge CB10 1SA, U.K.

<sup>†</sup>Present address: School of Chemistry, Joseph Black Building, West Mains Road, University of Edinburgh, Edinburgh EH9 3JJ, U.K.

Received: 19 March 2018

Revised: 10 July 2018

Accepted: 16 July 2018

Accepted Manuscript online:  
25 July 2018

Version of Record published:  
29 August 2018

**Table 1** List of primers used in the present study

Primer	Sequence
<i>Tc</i> AKR-F	<u>cat</u> ATGAATTGCAATTACAACGTGTGTGACACTCC
<i>Tc</i> AKR-R	<u>ggatcc</u> TCACTCCTCTCCACCAGGG
<i>Tb</i> PGFS-F	<u>cat</u> ATGGCTCTCACTCAATCCCTAAAACCTC
<i>Tb</i> PGFS-R	<u>ggatcc</u> TCAAAAGTCGTTTCATGAAGACCTCC
<i>Li</i> PGFS2-F	<u>aaaacat</u> ATGGCTGACGTTGGTAAGGCAATGG
<i>Li</i> PGFS2-R	<u>tttggatcc</u> TTAGAACTGCGCCTCATCGGGGTC
<i>Tc</i> PGF2 $\alpha$ -F	<u>cat</u> ATGGCGACGTTCCCCGAAC
<i>Tc</i> PGF2 $\alpha$ -R	<u>ggatcc</u> TTAGTTGTTGTACGTCGGGTAATCG

Restriction sites are underlined.

[15]. Somewhat paradoxically, the latter enzyme has been reported to activate benzimidazole, yet overexpression of AKR in *T. cruzi* decreased rather than increased susceptibility to benzimidazole [16]. Members of this AKR superfamily, characterised by their ability to reduce aldehydes and/or ketones, have been identified in all domains of life [17]. The activity of these enzymes requires either NADH and/or NADPH to reduce a variety of substrates, including, but not limited to aldoses, steroids, methylglyoxal [18] or prostaglandins [19]. In the trypanosomatid parasites *Leishmania* spp. and *T. brucei*, the production of prostaglandin F<sub>2 $\alpha$</sub>  has been reported to be catalysed by a member of the AKR family [19,20]; however, the equivalent enzyme in *T. cruzi* is reported not to catalyse this reaction [21]. Given the conflicting and contradictory reports in the literature, we have re-examined the ability of *Tc*AKR to metabolise benzimidazole and carried out a comparative enzymological study of trypanosomatid AKRs to elucidate their potential metabolic roles in prostanoic and glyoxal metabolism.

## Experimental procedures

### Cloning and expression of recombinant proteins

The open reading frames (ORFs) encoding *Li*PGFS1 (LinJ.32.0470, <http://tritrypdb.org>) and *Hs*PGFS (NP\_003730.4) were synthesised by GeneART™. The ORFs of *Tc*AKR (GenBank MH593394), *Tb*PGFS (Tb927.11.4700) and *Li*PGF2 (LinJ.31.2210) were amplified from genomic DNA isolated from *T. cruzi* Silvio X10/7 clone A1, *T. brucei* 427 and *Leishmania infantum* genomic DNA, respectively, using primers (Table 1) and pfu polymerase. The resulting PCR products were cloned into TOPO zero blunt. The ORFs of each gene were digested with the appropriate restriction endonucleases and ligated into pET15b-TEV, yielding pET15b-TEV-*Hs*PGFS, pET15b-TEV-*Tc*AKR, pET15b-TEV-*Li*PGFS1, pET15b-TEV-*Li*PGFS2 and pET15b-TEV-*Li*AKR. All plasmids were sequenced ([www.dnaseq.co.uk](http://www.dnaseq.co.uk)) to verify the correct sequences.

Plasmids were transformed into Rosetta (DE3) pLysS and 10-ml cultures were used to inoculate 1 l of Autoinduction medium [22] with shaking at 30°C for 12 h. Cells were harvested by centrifugation (5090×g for 30 min at 4°C) and resuspended in buffer A (25 mM sodium phosphate buffer, 300 mM NaCl and 25 mM imidazole, pH 8.0) supplemented with DNase I, lysozyme and complete EDTA-free protease inhibitor cocktail tablets (Roche). Cells were lysed at 30 kPsi using a continuous flow cell disruptor (Constant systems) and soluble proteins obtained by centrifugation (20 000×g, 30 min and 4°C). The soluble fraction was loaded onto a 5-ml HisTrap HP column and the bound protein eluted with a gradient of imidazole (0–250 mM) in buffer A. Fractions containing the protein of interest were pooled and the hexahistidine tag was removed with TEV protease overnight at 4°C while dialysing against 25 mM sodium phosphate, 300 mM NaCl, pH 8.0, in a 10 000 MWCO membrane. Pure protein was observed after a final HisTrap HP purification step.

### Oligomeric structure

Recombinant proteins were loaded onto a Superdex 75 10/300 or Superose 12 10/300 column, equilibrated in 25 mM HEPES, 150 mM NaCl, pH 7.33 and the elution volume of the recombinant proteins was compared with

that of known protein standards (Bio-Rad). *TcAKR* separations were also repeated using the Superose 12 10/300 column with the high salt buffer (150 mM Tris-HCl, pH 7.6, 300 mM NaCl) as previously described [21].

## Enzyme assays

Enzymatic activity was assessed by measuring the continuous oxidation of NADPH at 340 nm in the presence of varying concentrations of substrate using a Shimadzu UV-2401 or 1601 spectrophotometer. Measurements were taken under steady-state conditions, with a fixed concentration of NADPH (100  $\mu$ M) in 25 mM HEPES, 150 mM NaCl, pH 7.33, using an appropriate amount of enzyme. Enzyme concentrations for measuring the specific activities were quantified with the Bradford protein assay using bovine serum albumin as standard. Enzyme concentration for kinetic characterisation was determined by UV spectroscopy using the molar extinction coefficients of 37 735 for *HsPGFS*, 60 470 for *TcAKR*, 51 590 for *TbPGFS*, 52 930 for *LiPGFS1* and 51 530 for *LiPGFS2* calculated using CLC workbench version 6.9.1. The observed rate of change at 340 nm was converted into  $s^{-1}$  prior to fitting the data to the Michaelis–Menten kinetics equation in GraFit 5.0 yielding apparent values for  $k_{cat}$  and  $K_m$ . Reported values for  $K_m$  ( $K_m^{app}$ ) and  $k_{cat}$  values are the weighted mean of independent experiments. Weighted means and standard deviations were calculated using the following equations [23], where  $A, B \dots I$  are the means and  $a, b \dots i$  are standard deviations of  $A, B$ , etc.

Weighted mean of individual mean values

$$= \frac{(A/a^2) + (B/b^2) + \dots + (I/i^2)}{(1/a^2) + (1/b^2) + \dots + (1/i^2)}$$

Weighted mean of standard deviations

$$= \frac{(1/a) + (1/b) + \dots + (1/i)}{(1/a^2) + (1/b^2) + \dots + (1/i^2)}$$

## Recombinant prostaglandin $F_{2\alpha}$ synthase assay

A total of 1 mg of purified proteins (*TcAKR*, *LiPGFS1*, *LiPGFS2*, *TbPGFS*, *HsPGFS* and *TcOYE*) were incubated in the enzyme assay buffer in the presence of 10  $\mu$ M prostaglandin H<sub>2</sub> (Cayman Chemicals) and 100  $\mu$ M NADPH for 1 h at 37°C. Samples were inactivated by the addition of two volumes of acetonitrile and analysed by LC–MS/MS as described below for the analysis of arachidonic acid and a prostaglandin standard mixture (Cayman Chemicals).

## UPLC-QToF/MS analysis of benznidazole metabolism

Recombinant *TcAKR* (13  $\mu$ g and 130  $\mu$ g  $ml^{-1}$ ) was incubated with 100  $\mu$ M benznidazole and 100  $\mu$ M NADPH for 1 h at 37°C in 25 mM HEPES, 150 mM NaCl, pH 7.33. Hypotonic lysates (40 mg) made from *T. cruzi* wild-type or NTR1-overexpressing epimastigotes were incubated with 100  $\mu$ M benznidazole and 1 mM NADH as described above as a positive control. Reactions with pure enzyme or crude parasite lysates were terminated by the addition of two volumes of acetonitrile and analysed by UPLC-QToF/MS. Metabolite identification samples were analysed on a Waters Acquity UPLC coupled to a Waters Xevo QToF mass spectrometer. Chromatographic separation was achieved on a Waters BEH C18 column (50  $\times$  2.1 mm, 1.7  $\mu$ m particle size) eluted with A: water + 0.1% formic acid, B: acetonitrile + 0.1% formic acid. A flow rate of 0.5  $ml\ min^{-1}$  and an injection volume of 5  $\mu$ l were selected. Analysis was performed with a 7 min LC run: 98% A initially, to 65% A after 4 min then 5% A after 5 min, held for 0.99 min before returning to 98% A after 6 min. MS<sup>E</sup> spectra were acquired, allowing exact mass precursor and fragment data to be simultaneously collected over a mass range of 50–1200  $m/z$  with the following mass spectrometer parameters: positive electrospray ionisation, cone voltage 38 V, mass range 100–1200  $m/z$ , ramping collision energy 20–40 V, capillary voltage 1.5 kV, desolvation temperature 500°C, source temperature 120°C, desolvation gas (nitrogen) 800  $l\ h^{-1}$  and cone gas (nitrogen) 10  $l\ h^{-1}$ .

**Table 2 MRM transitions used for detecting the prostaglandin species and their retention times**

Chromatograms of the 10 min chromatographic separations are provided in Supplementary Figure S1.

Prostaglandin	MRM transition	Retention time (min)
6-keto PGF <sub>1α</sub>	369.2 > 163.1	3.09
Iso-PGF <sub>2α</sub>	353.0 > 192.9	4.25
PGF <sub>2α</sub>	353.0 > 192.9	4.88
PGF <sub>1α</sub>	355.2 > 311.2	4.96
PGE <sub>2</sub>	351.1 > 271.1	5.06
PGE <sub>1</sub>	353.2 > 317.2	5.31

## Parasite growth and electroporation

Epimastigotes of the *T. cruzi* strain Silvio X10/7 (MHOM/BR/78/Silvio; clone X10/7) clone A1 were grown RTH/FCS medium at 28°C [24]. *T. brucei* bloodstream-form parasites were grown in an HMI9-T [25] medium at 37°C and *Leishmania donovani* (MHOM/SD/62/1S-CL2D) promastigotes were grown in a modified M199 medium described previously [26]. Transgenic parasites overexpressing NTR1 (TCSYLIVIO\_001958) were generated by transfection of plasmid pTREX-TcNTR1 with an Amaxa Nucleofector 2b device using program U-33. Transgenic parasites were selected by the addition of G418 at 250 µg ml<sup>-1</sup>.

## Arachidonic acid co-culture experiment

*T. brucei* bloodstream-form parasites, *Leishmania donovani* promastigotes and *T. cruzi* epimastigotes, were incubated in the presence of 66 µM arachidonic acid (Sigma–Aldrich) for 16 h at 37°C, 28°C and 28°C, respectively. Parasites were collected by centrifugation and washed in PBS three times prior to biological inactivation by three rounds of freeze–thaw before mixing with two volumes of acetonitrile and analysis by LC–MS/MS.


## Lysate arachidonic acid experiment

*T. cruzi* epimastigotes and *T. brucei* BSF were harvested by centrifugation at 800×g and washed three times in ice cold PBS. Parasites (1 × 10<sup>8</sup>) were collected and lysed by hypotonic lysis (10 mM Tris–HCl, pH 7.5) for 5 min on ice. Incubations with and without 1 mM arachidonic acid were carried as previously described [19], in a reaction volume of 400 µl and reactions terminated by the addition of 800 µl acetonitrile. Samples were subjected to three rounds of freeze–thaw treatment to ensure biological inactivation, prior to analysis by LC–MS/MS. All samples were analysed on a Waters TQ-S with Acquity UPLC using a Waters BEH C18 column (50 × 2 mm, 1.7 µm particle size). Source temperature was 150°C and desolvation gas temperature was 600°C. Eluents used were A: water + 0.01% formic acid, B: acetonitrile + 0.01% formic acid and the flow rate was 0.5 ml min<sup>-1</sup>. Initial work on the incubation of arachidonic acid with parasites was performed with a 6 min LC run: 95% A initially, to 80% A after 1 min then 60% A after 4 min, to 5% A after 4.5 min, held for 0.5 min before returning to 95% A after 5.1 min. Further work on the incubation of arachidonic acid with cell lysates was performed with a 10 min LC run: 95% A initially, to 80% A after 1 min then 60% A after 8 min, to 5% A after 8.1 min, held for 0.9 min before returning to 95% A after 9.1 min. Multiple reaction monitoring (MRM) transitions used for the prostaglandin species monitored are listed in Table 2 and Supplementary Figure S1 (all in negative ion mode).

## Results

### Characterisation of TcAKR

The enzymatic function of TcAKR is far from clear: it is annotated as a prostaglandin F synthase in some genomic databases, yet the recombinant protein is reported to lack such activity [21] and other possible physiological substrates have not been tested. It has also been proposed that TcAKR plays a role in the metabolism of, and resistance to, benznidazole [15,16]. To clarify these issues, TcAKR was expressed in *Escherichia coli*, purified to homogeneity (Figure 1A) and its physico-chemical properties were determined. The purified protein (with or without the His<sub>6</sub>-tag) was analysed by size exclusion chromatography and found to elute as a single symmetrical peak with a calculated M<sub>r</sub> close to that of a theoretical monomer (Figure 1B), when separated



**Figure 1. Characterisation of recombinant *TcAKR*.**

(A) Purity of recombinant enzyme by SDS–PAGE: insoluble (lane 1), soluble (lane 2), pooled fraction after HisTrap (lane 3) and pooled protein after hexahistidine tag removal (lane 4). (B) Elution profile of recombinant *TcAKR* (black) and His<sub>6</sub>-*TcAKR* (blue) under quasi-physiological conditions from a Superdex 75 10/300 column. (Inset) Elution volumes of known protein standards (open circles) plotted against the log<sub>10</sub> of their molecular masses. Theoretical elution volume of the *T. cruzi* AKR monomer (closed circle). Linear fit  $R^2$ : 0.998. (C) Elution profile of recombinant *TcAKR* at 2 mg ml<sup>−1</sup> (black) and 20 mg ml<sup>−1</sup> (blue) under quasi-physiological conditions from a Superose12 10/300 column.

under quasi-physiological conditions (pH 7.33, 150 mM NaCl). This finding is in complete contrast with that of a previous study by Garavaglia et al. [21], who reported the presence of mixed species containing monomeric, dimeric and tetrameric forms of the enzyme from the CL-Brener strain of *T. cruzi*. When repeating these authors' conditions using the same column and buffer conditions, the *TcAKR* isolated from our laboratory strain of *T. cruzi* continued to elute as a monomeric species, irrespective of the amount loaded (Figure 1C). The reason for this discrepancy is not clear. Both enzymes are highly similar (97% amino acid sequence identity); however, modelling onto the published crystal structure of this enzyme [27] suggests that the majority of these differences are located on the surface. Notably, one allele in the CL-Brener strain contains an additional cysteine (Y51C) (SNP: NGS\_SNP.TcChr40-P.486408), which is absent in the Silvio X10-7 clone used in our study. Modelling on the *TcAKR* crystal structure 4GIE [27] suggests that this cysteine residue is likely to be solvent accessible and therefore available for disulfide formation with another monomer. This could account for dimer (but not the tetramer) species reported by Garavaglia et al. [21] and would explain why their dimeric species did not dissociate into monomers during mass spectrometry.

## Substrate-specificity of *TcAKR*

As *TcAKR* has no clear biological role, a BLAST analysis was carried out in an attempt to assign a possible function for this enzyme, identifying enzymes in vitamin K biosynthesis, glyoxal metabolism and synthesis of prostaglandin F<sub>2α</sub>. The activity of *TcAKR* was assessed with a fixed concentration of a variety of biologically relevant or typical AKR substrates (Table 3) identifying methylglyoxal, a toxic by-product of glycolysis, to have one of the highest specific activities with the purified enzyme. Subsequent characterisation of glyoxal and




**Table 3 A survey of purified recombinant trypanosomatid aldo-keto reductases with various substrates**

Compounds (60  $\mu$ M) were assayed spectrophotometrically in the presence of 100  $\mu$ M NADPH. Specific activity is given in  $\mu$ mol min<sup>-1</sup> mg<sup>-1</sup>. Values are the means and standard deviations ( $n = 3$ ).

Substrate	<i>TcAKR</i>	<i>LiPGFS1</i>	<i>LiPGFS2</i>	<i>TbPGFS</i>
2-Nitrobenzaldehyde	0.20 $\pm$ 0.004	1.40 $\pm$ 0.04	2.51 $\pm$ 0.029	0.73 $\pm$ 0.017
3-Nitrobenzaldehyde	0.16 $\pm$ 0.003	0.06 $\pm$ 0.002	2.40 $\pm$ 0.037	1.86 $\pm$ 0.009
4-Nitrobenzaldehyde	0.39 $\pm$ 0.009	0.06 $\pm$ 0.002	2.49 $\pm$ 0.142	0.71 $\pm$ 0.013
Glyoxal	0.001 $\pm$ 0.001	0.02 $\pm$ 0.001	0.09 $\pm$ 0.001	0.15 $\pm$ 0.005
Methylglyoxal	1.20 $\pm$ 0.022	0.61 $\pm$ 0.02	1.79 $\pm$ 0.009	0.67 $\pm$ 0.012
Phenylglyoxal	3.66 $\pm$ 0.092	3.11 $\pm$ 0.018	2.46 $\pm$ 0.084	0.78 $\pm$ 0.037
Vitamin K3 epoxide	N.A.	N.A.	N.D.	N.A.
Glyceraldehyde	0.05 $\pm$ 0.005	N.D.	0.16 $\pm$ 0.002	0.13 $\pm$ 0.004
Benznidazole	N.A.	N.A.	N.A.	N.A.

Abbreviations: NA, not active; ND, not determined.

methylglyoxal showed them to follow Michaelis–Menten kinetics (Figure 2A,B). Notably, methylglyoxal had a  $K_m$  of 0.24 mM and  $k_{cat}/K_m$  ( $1.95 \times 10^4$  M s<sup>-1</sup>) which is similar to that of SakRI ( $1.1 \times 10^4$  M<sup>-1</sup> s<sup>-1</sup>), a cyano-bacterial enzyme involved in methylglyoxal detoxification [18].




**Figure 2. Testing benznidazole as a substrate or inhibitor of recombinant *TcAKR*.**

(A) Benznidazole as a substrate of *TcAKR*, DMSO (open circles), 60  $\mu$ M benznidazole (closed circles), 60  $\mu$ M phenylglyoxal (open squares). (B) Inhibition of phenylglyoxal (60  $\mu$ M) metabolism by benznidazole, DMSO (closed circles), 60  $\mu$ M benznidazole (open circles). (C and D) Michaelis–Menten plots of activity with glyoxal and methylglyoxal, respectively.

Although benznidazole was recently reported to be a substrate of this enzyme ( $73 \text{ mU mg}^{-1}$ ) [16], we were unable to detect any increase in NADPH oxidation above the background rate ( $1 \text{ mU mg}^{-1}$ ) when benznidazole was present at  $60 \mu\text{M}$  (Figure 2C). Neither did we observe any inhibition of enzymatic activity by benznidazole with phenylglyoxal as a substrate (Figure 2D). To confirm our negative findings with the spectrophotometric assay, the purified enzyme was incubated with NADPH in the presence or absence of benznidazole for 1 h at  $37^\circ\text{C}$  and subsequently analysed by UPLC-QToF/MS. Even in the presence of excess enzyme ( $130 \mu\text{g ml}^{-1}$ ), we were unable to detect any utilisation of benznidazole (Figure 3A,B). In contrast, incubation of benznidazole with parasite lysates under identical conditions converted more than half of the benznidazole (Figure 3C,D) into multiple metabolites already reported in the literature (Table 4) [8,10]. The smaller peak size of benznidazole incubated with the lysate prepared from NTR-overexpressing parasites (Figure 3D) is consistent with NTR-activating benznidazole [8]. Other clinically pertinent nitro-drugs for the trypanosomatid parasites, nifurtimox, fexinidazole [5] and (R)-PA824 [28] were also not substrates for AKR. These results demonstrate that TcAKR is not directly involved with the bio-activation of benznidazole or other nitro-drugs.

### Identifying alternative methylglyoxal-reducing enzymes in the trypanosomatids

Homologues of TcAKR were identified in the related parasites *T. brucei* and *L. infantum*, identifying one and two homologues, respectively. The identification of a *T. brucei* homologue was of particular interest as this parasite notably lacks the trypanothione-dependent glyoxalase pathway present in *Leishmania* and *T. cruzi* [29]. The genes encoding these enzymes have been annotated as prostaglandin F synthases, with the *L. infantum* (LinJ.31.2210) and *T. brucei* (Tb927.11.4700) sequences previously assigned to AKR sub-family 5A [17]. Alignments revealed the trypanosomatid sequences to share between 54 and 57% identity with each other (Figure 4) with all maintaining the conserved AKR catalytic tetrad identified in *T. brucei* [30]. To further characterise the enzymatic properties of these proteins, the homologues identified from *T. brucei* and *L. infantum* were overexpressed in *E. coli* and purified to homogeneity using the same two-stage purification as for TcAKR (Figure 5A). The typical yields of pure protein ranged between 10 and  $30 \text{ mg l}^{-1}$  of starting culture. Similar to TcAKR, the homologues TbPGFS, LiPGFS1 and LiPGFS2 were primarily monomeric (Figure 5B–D) when analysed by size exclusion chromatography under the same quasi-physiological conditions. However, when LiPGFS1 was incubated for 96 h at  $4^\circ\text{C}$  in the absence of a reducing agent, 25% of the protein eluted with an apparent mass of a dimer (Figure 5E). The addition of a reducing agent completely abolished the dimeric species (Figure 5E), indicating the dimeric form to be reliant upon disulfide bond formation.



**Figure 3. Metabolism of benznidazole by TcAKR and whole cell lysates of *T. cruzi*.**

Extracted ion chromatograms measuring the relative amount of benznidazole in the presence of NADH plus (A) no enzyme, (B)  $0.13 \text{ mg ml}^{-1}$  recombinant TcAKR, (C)  $40 \text{ mg ml}^{-1}$  of a wild-type *T. cruzi* lysate and (D)  $40 \text{ mg ml}^{-1}$  of a lysate-overexpressing NTR.



**Table 4 Benznidazole-derived metabolites**

Metabolites were identified by accurate mass and presence in the sample, but absence in the control incubations.

Retention time (min)	Structure	Metabolite number <sup>1</sup>	[M + H] <sup>+</sup>	Ionisation state	WT lysate	NTR <sup>OE</sup> Lys B	Control	TcAKR
3.1	Benznidazole	NA	261.10	1	NA	NA	NA	NA
1.59	Hydroxylamine or hydroxy derivative 1 or 2	11 or 19	247.11	1	Y	Y	N	N
1.8	Amino derivative of benznidazole	1	231.12	1	Y	Y	N	N
1.49/1.59	Dihydroxy-dihydro derivative	3	265.13	1	Y	Y	N	N
1.59	<i>N</i> -benzyl-2-guanidinoacetamide	5	207.13	1	N	Y	N	N
1.3	2-Amino- <i>N</i> -benzylacetamide	22	165.10	1	Y	Y	N	N
1.74	Amino derivative + glutathione (isomer 1)	7 or 8	536.19 268.56	1 2	Y Y	Y Y	N N	N N
1.83	Amino derivative + glutathione (isomer 2)	7 or 8	536.19 268.56	1 2	Y Y	Y Y	N N	N N
1.55/1.64	Amino derivative + glutathione + H <sub>2</sub> O	4	554.20 277.60	1 2	Y Y	Y Y	N N	N N
1.76/1.93/2.31	Amino derivative + cysteine	9	350.13	1	Y	Y	NN	NN
1.34	Amino derivative + ovothiol A	12 or 14	430.17 215.58	1 2	Y Y	Y Y	N N	N N
3.8	Possible benznidazole adduct	26	385.18	1	Y	Y	N	N
1.63	Possible benznidazole adduct	28	368.12	1	N	Y	N	N
3.64/3.8	Possible benznidazole adduct	NA	614.35	1	Y	Y	N	N
2.13	Possible benznidazole metabolite	NA	204.05	1	Y	Y	N	N

Abbreviations: NA, not applicable.


<sup>1</sup>The metabolite numbers refer to the metabolite list in Trochine et al. [10].

## Comparative kinetics of trypanosomatid AKRs

The enzymatic properties of the three additional purified homologues were assessed with the same substrates tested against *TcAKR*, finding that all of the trypanosomatid enzymes were capable of using the same substrates (Table 3). Similar to *TcAKR*, neither the *Leishmania* nor *T. brucei* enzymes were capable of using the nitro-drugs benznidazole or nifurtimox as substrates. As the homologues displayed identical substrate usage, the basic kinetic parameters of each enzyme for each of the substrates were determined at a fixed concentration of NADPH (Table 5). Comparing the apparent  $K_m^{app}$  values, substrate turnover rates and catalytic efficiencies of the enzymes revealed *LiPGFS1* to be more kinetically similar to the *TcAKR* than *TbPGFS*, with the opposite relationship true of *LiPGFS2* suggesting a divergence in AKR evolution in *Leishmania*. We observed the catalytic efficiency ( $k_{cat}/K_m$ ) of methylglyoxal as a substrate of these enzymes to be relatively unchanged despite up to 20- and 80-fold differences  $k_{cat}$  and  $K_m$  values, respectively. This trend also was observed for glyoxal, phenylglyoxal and D,L-glyceraldehyde. However, the nitro-aromatic compounds were much more efficiently utilised in the case of *TbPGFS* or *LiPGFS2* compared with *LiPGFS1* and *TcAKR*. *LiPGFS2* used in our study appears to be the same as a glutathione-specific aldose reductase [31]; however, it appears that glutathione is not required for the functional activity of this enzyme in our hands. The human prostaglandin  $F_{2\alpha}$  synthase (NP\_003730.4) also displayed trace activity with methylglyoxal as a substrate, but with a much lower efficiency ( $\sim 10 \text{ M}^{-1} \text{ s}^{-1}$ ), indicating that it is unlikely to be a functional mechanism for detoxification of methylglyoxal in human cells.

## Arachidonic acid and prostaglandins


Previous studies on these enzymes have suggested that the *T. brucei* and *Leishmania* spp. AKRs function as prostaglandin  $F_{2\alpha}$  synthases in these parasites, converting prostaglandin  $H_2$  ( $\text{PGH}_2$ ) to the  $F_{2\alpha}$  form. While our observations for prostaglandin  $F_{2\alpha}$  synthase activity of *TbPGFS* and *LiPGFS2* were in agreement with the literature [19,20], we also observed  $\text{PGF}_{2\alpha}$  activity for *LiPGFS1* (Table 6). We also confirm the lack of prostaglandin  $F_{2\alpha}$  synthase activity of *TcAKR* as reported by Garavaglia et al. [21].



**Figure 4. Sequence alignment of AKR homologues identified by BLAST.**

Multiple sequence alignment of SakRI, TcAKR (TcCLB.511287.49), LiPGFS1 (LinJ.31.2210), LiPGFS2 (LinJ.32.0470) and TbPGFS (Tb927.11.4700). The conserved AKR catalytic tetrad identified in *T. brucei* is marked by the red boxes. Blue boxes indicate solvent accessible cysteine residues identified in the crystal structures of TbPGFS, TcAKR and LiPGFS2 (PDB accession numbers 1VBJ, 4GIE and 4G5D) [27]. Orange box highlighting Y51C allelic variation was observed in CL-Brener.

Observations that these parasites are capable of synthesising PGH<sub>2</sub> from arachidonic acid currently do not fit with the known prostaglandin biosynthetic pathway due to the absence of cyclooxygenases 1 and 2 that catalyse the conversion of arachidonic acid to PGH<sub>2</sub>. Our alternative hypothesis is that the formation of the prostaglandins from arachidonic acid could be due to the formation of structurally similar isomers, the isoprostanes. These molecules have been reported as a marker of oxidative stress [34] and are formed by the free radical-mediated peroxidation of arachidonic acid within the cell [35]. In contrast with enzyme-mediated peroxidation that typically generates a single enantiomer of a single regioisomer, non-enzymatic peroxidation generates racemic mixtures with multiple regio- and stereo-centres [36,37]. Among other products, non-enzymatic peroxidation of arachidonic acid produces four F<sub>2</sub>-isoprostane regioisomers (Figure 6), each of which comprises eight racemic diastereomers, making 64 in total [38]. Prostaglandin F<sub>2α</sub> and its isoprostane 8-isoprostane F<sub>2α</sub> (15-F<sub>2t</sub>-IsoP or iPF<sub>2α</sub>-III) belong to the 15-series regioisomers, which, together with the 5-series, are formed in greater amounts than the less stable 8- and 12-series [38]. Although the four F<sub>2</sub>-isoprostane classes are isobaric (*m/z* 353), they can be distinguished by their MRM spectra which yield different fragmentation patterns below *m/z* 200, with the 15-series (iPF<sub>2α</sub>-III series) producing a predominant 193 anion [39]. The 5-series produces a minor peak at 193, but can be distinguished by its predominant MRM product at *m/z* 115 and different retention time on HPLC. To determine if prostaglandins or isoprostanes could be produced, parasites were co-incubated with arachidonic acid and analysed by LC–MS/MS and compared with known analytical standards. Despite the high sensitivity of the LC–MS/MS assay (LOD of ~0.1 ng ml<sup>−1</sup> for both species) our initial experiments, where 66 μM arachidonic acid was co-incubated with intact parasites, failed to detect either prostaglandin F<sub>2α</sub> or its isoprostane 8-isoprostane F<sub>2α</sub>. However, the addition of 1 mM arachidonic acid to hypotonic lysates of *T. brucei* or *T. cruzi* led to the production of multiple isomeric peaks on the MRM channel for



**Figure 5. Characterisation of *LiPGFS1*, *LiPGFS2* and *TbPGFS*.**

(A) SDS-PAGE showing purification of *TbPGFS1*, *LiPGFS1* and *LiPGFS2* showing insoluble, soluble, pooled protein from HisTrap column and protein with the hexahistidine tag removed. Size exclusion elution profiles of (B) *TbPGFS*, (C) *LiPGFS1* and (D) *LiPGFS2*. Samples were separated on a Superose 12 10/300 column in 25 mM HEPES, 150 mM NaCl, pH 7.33. (E) *LiPGFS1* stored in the absence of a reducing agent analysed by size exclusion chromatography in the absence (blue) and presence (red) of 0.5 mM TCEP using a Superdex 75 10/300 column.

**Table 5 Kinetic characterisation of trypanosomatid recombinant aldo-keto reductases with various substrates**

Substrate	Units	<i>Tc</i> AKR	<i>Li</i> PGFS1	<i>Li</i> PGFS2	<i>Tb</i> PGFS
Glyoxal					
$k_{\text{cat}}$	$\text{s}^{-1}$	$4.56 \pm 0.05$	$7.31 \pm 0.19$	$1.05 \pm 0.02$	ND
$K_{\text{m}}^{\text{app}}$	mM	$8.30 \pm 0.31$	$36.1 \pm 2.39$	$0.56 \pm 0.05$	ND
$k_{\text{cat}}/K_{\text{m}}^{\text{app}}$	$\text{M}^{-1} \text{s}^{-1}$	549	202	1880	ND
Methylglyoxal					
$k_{\text{cat}}$	$\text{s}^{-1}$	$4.69 \pm 0.03$	$8.72 \pm 0.17$	$1.13 \pm <0.01$	$0.38 \pm 0.007$
$K_{\text{m}}^{\text{app}}$	mM	$0.24 \pm <0.001$	$0.80 \pm 0.07$	$0.02 \pm <0.001$	$0.01 \pm <0.001$
$k_{\text{cat}}/K_{\text{m}}^{\text{app}}$	$\text{M}^{-1} \text{s}^{-1}$	19 500	10 900	56 500	38 000
Phenylglyoxal					
$k_{\text{cat}}$	$\text{s}^{-1}$	$4.46 \pm 0.08$	$10.4 \pm 0.22$	$1.17 \pm 0.02$	$0.34 \pm 0.014$
$K_{\text{m}}^{\text{app}}$	mM	$0.05 \pm 0.003$	$0.14 \pm 0.008$	$0.01 \pm 0.0009$	$0.005 \pm 0.0008$
$k_{\text{cat}}/K_{\text{m}}^{\text{app}}$	$\text{M}^{-1} \text{s}^{-1}$	89 200	74 300	58 500	68 000
2-Nitrobenzaldehyde					
$k_{\text{cat}}$	$\text{s}^{-1}$	$2.25 \pm 0.11^2$	$8.50 \pm 0.21$	$1.04 \pm 0.02$	$0.41 \pm 0.002$
$K_{\text{m}}^{\text{app}}$	mM	$0.71 \pm 0.08^2$	$0.32 \pm 0.02$	$0.0024 \pm 0.0003$	$0.003 \pm 0.0003$
$k_{\text{cat}}/K_{\text{m}}^{\text{app}}$	$\text{M}^{-1} \text{s}^{-1}$	3170	26 600	433 000	140 000
3-Nitrobenzaldehyde					
$k_{\text{cat}}$	$\text{s}^{-1}$	$4.07 \pm 0.17$	$1.28 \pm 0.03$	$1.04 \pm 0.02$	$0.34 \pm 0.005$
$K_{\text{m}}^{\text{app}}$	mM	$2.20 \pm 0.16$	$1.55 \pm 0.06$	$0.002 \pm 0.0003$	$0.002 \pm 0.0001$
$k_{\text{cat}}/K_{\text{m}}^{\text{app}}$	$\text{M}^{-1} \text{s}^{-1}$	1850	830	520 000	170 000
4-Nitrobenzaldehyde					
$k_{\text{cat}}$	$\text{s}^{-1}$	$3.7 \pm 0.15$	$0.48 \pm 0.01$	$1.13 \pm 0.05^2$	$0.43 \pm 0.008$
$K_{\text{m}}^{\text{app}}$	mM	$68 \pm 0.07$	$0.43 \pm 0.026$	$0.004 \pm 0.0006^2$	$0.0043 \pm 0.0002$
$k_{\text{cat}}/K_{\text{m}}^{\text{app}}$	$\text{M}^{-1} \text{s}^{-1}$	5440	1 110	283 000	100 000
D,L-glyceraldehyde					
$k_{\text{cat}}$	$\text{s}^{-1}$	$4.94 \pm 0.11$	$8.72 \pm 0.11^2$	$2.46 \pm 0.13^2$	$0.37 \pm 0.009$
$K_{\text{m}}^{\text{app}}$	mM	$1.50 \pm 0.17$	$2.87 \pm 0.08^2$	$1.07 \pm 0.15^2$	$0.07 \pm 0.005$
$k_{\text{cat}}/K_{\text{m}}^{\text{app}}$	$\text{M}^{-1} \text{s}^{-1}$	3290	3040	2300	5290

Abbreviations: ND, not determined.

<sup>1</sup> $K_{\text{m}}^{\text{app}}$  values determined with 100  $\mu\text{M}$  NADPH.

<sup>2</sup>Weighted mean of two individual replicates, all others are  $n \geq 3$ .

PGF<sub>2 $\alpha$</sub>  and iso-PGF<sub>2 $\alpha$</sub>  (Figure 7). A clearly resolved peak was detected for iso-PGF<sub>2 $\alpha$</sub> , along with a shoulder with the same retention time as PGF<sub>2 $\alpha$</sub> . The identity of the other peaks is not known, but is likely to include the other racemic diastereoisomers in the 15-series (Figure 6). Similar results were obtained for both *T. brucei* and *T. cruzi*.

## Discussion


The primary aim of the present study was to assess the capability of *Tc*AKR to reduce or bio-activate clinically relevant monocyclic and bicyclic nitro-drugs that are either in clinical use or under development for the treatment of Chagas disease. Garavaglia et al. [16] reported that recombinant *Tc*AKR and native *Tc*AKR purified from *T. cruzi* epimastigotes were able to reduce benznidazole with specific activities of 0.091 and 0.073 U mg<sup>−1</sup>, respectively. In complete contrast, we found no evidence for the reduction of benznidazole by *Tc*AKR

**Table 6 Identification of prostaglandin  $F_{2\alpha}$  synthase activity in trypanosomatid aldo-keto reductases and old yellow enzyme**

Enzyme	Peak area			
	PGF <sub>2α</sub>	PGF <sub>1α</sub>	PGE <sub>2</sub>	PGE <sub>1</sub>
No enzyme control	3185		176 250	984
<i>Hs</i> PGFS	6415		187 319	537
<i>Tc</i> AKR	4231		190 097	1161
<i>Li</i> PGFS1	33 807	536	156 739	393
<i>Li</i> PGFS2	38 285	467	149 112	273
<i>Tb</i> PGFS	28 568	306	139 483	606
<i>Tc</i> OYE	25 216	510	133 298	353


Enzymes were incubated with PGH<sub>2</sub> as described in Experimental Procedures and analysed by LC–MS. 6-Keto-PGF<sub>2α</sub> and iso-PGF<sub>2α</sub> were not detected. PGH<sub>2</sub> is unstable and in the absence of enzyme is spontaneously rearranged to PGE<sub>2</sub> [32,33].

(<0.001 U mg<sup>−1</sup>) (Table 3); neither could we detect metabolism of benznidazole by *Tc*AKR using UPLC-QToF/MS under conditions where extensive metabolism occurred in whole cell lysates (Figure 3 and Table 4). It is unlikely that amino acid substitutions in these AKRs are responsible for the discrepancy, because the CL-Brener and Silvio enzymes are 97% identical and molecular modelling shows that the active sites are identical. Differences in assay conditions could be a possible explanation: our assays were at pH 7.33 in HEPES buffer, whereas Garavaglia et al. used Tris–HCl, pH 6.5—an inappropriate buffer system since the pK<sub>a</sub> for Tris is 8.3. Notably, these authors reported difficulties in measuring catalytic activity because of non-enzymatic reaction between benznidazole and NADPH cofactor under their experimental conditions. We did not encounter any such problem when pure recombinant *Tc*AKR was assayed under our conditions by spectrophotometry (Figure 2) or by mass spectrometry (Table 4). We conclude that *Tc*AKR is not involved in the bioactivation of benznidazole, but instead we offer a potential role for *Tc*AKR in resistance to benznidazole as discussed below.



**Figure 6. Formation of F<sub>2</sub>-isoprostanes from arachidonic acid.**

Abbreviations: IsoP, isoprostane.




**Figure 7. MRM chromatograms monitoring for PGF2 $\alpha$  /Iso-PGF2 $\alpha$  in *T. cruzi* cell lysates.**

Elution profile of 2 ng ml<sup>-1</sup> standards of iso-PGF2 $\alpha$  (A) and PDF2 $\alpha$  (B). *T. cruzi* cell lysates incubated with (D) or without (C) 1 mM arachidonic acid.

A second aim of our study was to elucidate the possible metabolic functions of these AKR homologues across the Trypanosomatidae. All four enzymes across three representative species possess activity with ketoaldehydes with specificity constants ( $k_{\text{cat}}/K_m$ ) in the order phenylglyoxal > methylglyoxal > glyoxal. Notably, all four enzymes had specificity constants for methylglyoxal (range 1.1–5.7 [ $\times 10^4$ ] M s<sup>-1</sup>) that are similar to that of SakRI (1.1  $\times 10^4$  M<sup>-1</sup> s<sup>-1</sup>), a bacterial enzyme that has been implicated in methylglyoxal metabolism [18]. The specificity constant for *Tb*PGFS with methylglyoxal (3.8  $\times 10^4$  M<sup>-1</sup> s<sup>-1</sup>) is an order of magnitude lower than that reported with PGH<sub>2</sub> (7  $\times 10^5$  M<sup>-1</sup> s<sup>-1</sup>) [30], whereas the reverse is observed for *Li*PGFS2 with methylglyoxal (5.7  $\times 10^4$  M<sup>-1</sup> s<sup>-1</sup>) preferred over PGH<sub>2</sub> (8.8  $\times 10^3$  M<sup>-1</sup> s<sup>-1</sup>) [20]. As previously reported [21] and confirmed here, the *T. cruzi* enzyme lacks prostaglandin F synthase activity; this is provided instead by old yellow enzyme [32], a protein that is absent in *T. brucei* and *L. infantum*. Given the broad spectrum of activity with ketoaldehydes, aromatic aldehydes, erythroses (the present study) and quinones [16,19,40], these enzymes are more like carbonyl reductases (EC 1.1.1.184) [41] than prostaglandin F synthases (EC 1.1.1.188). Of the



In the case of *TcAKR*, overexpression of this enzyme confers a modest resistance to benznidazole [16]. Benznidazole is a prodrug and undergoes activation via two sequential two-electron reduction steps by a mitochondrial nitroreductase to form a toxic reactive hydroxylamine intermediate (Figure 8). This compound subsequently forms adducts with low molecular mass thiols [10] or undergoes rearrangement to a



The metabolites shaded in grey were identified in our study (Table 4). The removal of glyoxal by AKR promotes further metabolism to 2-amino-*N*-benzyl acetamide.

dihydro-dihydroxy intermediate [8] that can dissociate to form glyoxal and *N*-benzyl-2-guanidinoacetamide [54] (Figure 8). Glyoxal is toxic and mutagenic and reacts with DNA to form a cyclic glyoxal-deoxyguanosine adduct, as well as causing deamination of deoxycytidine and cross-linking in DNA [55]. Thus, overexpression of *TcAKR* may contribute to benznidazole resistance by facilitating removal of glyoxal.

Given the absence of genetic and biochemical evidence for cyclooxygenase-dependent synthesis of  $\text{PGH}_2$  from arachidonic acid [19,20,32], the evidence for specific prostaglandin metabolism requires critical reassessment. In mammalian tissues, non-cyclooxygenase-derived  $\text{F}_2$ -isoprostanes can be formed *in situ* on arachidonic acid-containing phospholipids via lipid peroxidation and then released by the action of phospholipase  $\text{A}_2$  [35]. Alternatively, they can be formed from free arachidonic acid *in vitro* [56]. *Leishmania* spp. are able to synthesise arachidonic acid *de novo* [57], whereas *T. cruzi* and *T. brucei* are able to scavenge it from the extracellular medium and incorporate it into lipid bodies [57–59]. All species contain phospholipase  $\text{A}_2$  [60,61]. Our findings support the non-enzymatic formation of  $\text{PGH}_2$  and other  $\text{F}$ -type isoprostanes by free radical peroxidation of arachidonic acid. Notably, the formation of multiple isobaric products ( $m/z$  353) with the characteristic MRM signal for the 15-series of  $\text{F}$ -type prostanoids ( $m/z$  193) supports a non-enzymatic peroxidation mechanism, in contrast with a cyclooxygenase-catalysed peroxidation that would generate a single enantiomerically pure product [36,37]. In this respect, it is worth noting that the four studies reporting enzymatic conversion of arachidonic acid into  $\text{PGD}_2$ ,  $\text{PGE}_2$  and  $\text{PGF}_{2\alpha}$  utilised an analytical approach that focuses exclusively on these prostanoids [19,32,40,59] and predates the discovery of isoprostanes. The method involves incubation of whole cell lysates with saturating amounts of arachidonic acid, spiking with trace amounts of radiolabelled  $\text{PGD}_2$ ,  $\text{PGE}_2$  and  $\text{PGF}_{2\alpha}$ , separation by HPLC and quantitation of radiolabelled peaks by enzyme immunoassay [62]. Thus, the large number of additional  $\text{F}_2$ -isoprostane metabolites observed here (Figure 7) may have been missed. We propose that arachidonic acid (free or as phospholipid) undergoes non-enzymatic peroxidation to form 8-iso- $\text{PGH}_2$  (among other enantiomers) which serves as a substrate for AKRs to form 8-iso- $\text{PGF}_{2\alpha}$  (and other isoprostanes). Additionally, we note that a report that *T. cruzi* produces thromboxane  $\text{A}_2$  as well as  $\text{PGF}_{2\alpha}$  [63] could also involve a non-enzymatic pathway [64]. Thus, there is a need for a thorough re-evaluation of the nature of eicosanoids formed in these parasites and the possible physiological role of the products. For example, it is worth noting that host immune responses to parasite infection often involve oxidant stress [65,66] and that certain prostanoids formed via the free radical route can have biological activity [67].

In conclusion, we have demonstrated that the substrate-specificity of these aldo-keto reductases is broader than other prostaglandin  $\text{F}_{2\alpha}$  synthases and that they are likely to be involved in the elimination of certain toxic ketoaldehyde metabolites derived from lipids, trioses and the drug, benznidazole.

## Abbreviations

AKR, aldo-keto reductase; MRM, multiple reaction monitoring; NTR, nitroreductase; ORFs, open reading frames;  $\text{PGF}_{2\alpha}$ , prostaglandin  $\text{F}_{2\alpha}$ ;  $\text{PGH}_2$ , prostaglandin H.

## Author Contribution

A.H.F. conceived the project. A.J.R., S.N., P.S. and A.H.F. designed the experiments. A.J.R., J.D., S.N. and P.S. performed the experiments. All authors analysed the data and contributed to the manuscript.

## Funding

This work was supported by a grant from the Wellcome Trust [079838] with additional co-funding from the Wellcome Trust/Bill and Melinda Gates Foundation [OPP1066891]. J.D. was supported by a James Black prize studentship funded by the University of Dundee.

## Acknowledgements

We thank the DNA sequencing service at the University of Dundee and the Ferguson group for the use of their Superose 12 column.

## Competing Interests

The Authors declare that there are no competing interests associated with the manuscript.

## References

- 1 Stuart, K., Brun, R., Croft, S., Fairlamb, A., Gürtler, R.E., McKerrow, J. et al. (2008) Kinetoplastids: related protozoan pathogens, different diseases. *J. Clin. Invest.* **118**, 1301–1310 <https://doi.org/10.1172/JCI33945>
- 2 Feasey, N., Wansbrough-Jones, M., Mabey, D.C.W. and Solomon, A.W. (2010) Neglected tropical diseases. *Br. Med. Bull.* **93**, 179–200 <https://doi.org/10.1093/bmb/ldp046>
- 3 Eperon, G., Balasegaram, M., Potet, J., Mowbray, C., Valverde, O. and Chappuis, F. (2014) Treatment options for second-stage gambiense human African trypanosomiasis. *Expert Rev. Anti. Infect. Ther.* **12**, 1407–1417 <https://doi.org/10.1586/14787210.2014.959496>
- 4 Bahia, M.T., de Andrade, I.M., Martins, T.A.F., da Silva do Nascimento, A.F., Diniz, L.F., Caldas, I.S. et al. (2012) Fexinidazole: a potential new drug candidate for Chagas disease. *PLoS Negl. Trop. Dis.* **6**, e1870 <https://doi.org/10.1371/journal.pntd.0001870>
- 5 Wyllie, S., Patterson, S., Stojanovski, L., Simeons, F.R.C., Norval, S., Kime, R. et al. (2012) The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. *Sci. Transl. Med.* **4**, 119re1 <https://doi.org/10.1126/scitranslmed.3003326>
- 6 Kaiser, M., Bray, M.A., Cal, M., Bourdin Trunz, B., Torreale, E. and Brun, R. (2011) Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. *Antimicrob. Agents Chemother.* **55**, 5602–5608 <https://doi.org/10.1128/AAC.00246-11>
- 7 Wilkinson, S.R., Taylor, M.C., Horn, D., Kelly, J.M. and Cheeseman, I. (2008) A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. *Proc. Natl Acad. Sci. U.S.A.* **105**, 5022–5027 <https://doi.org/10.1073/pnas.0711014105>
- 8 Hall, B.S. and Wilkinson, S.R. (2012) Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. *Antimicrob. Agents Chemother.* **56**, 115–123 <https://doi.org/10.1128/AAC.05135-11>
- 9 Hall, B.S., Bot, C. and Wilkinson, S.R. (2011) Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. *J. Biol. Chem.* **286**, 13088–13095 <https://doi.org/10.1074/jbc.M111.230847>
- 10 Trochine, A., Creek, D.J., Faral-Tello, P., Barrett, M.P. and Robello, C. (2014) Benznidazole biotransformation and multiple targets in *Trypanosoma cruzi* revealed by metabolomics. *PLoS Negl. Trop. Dis.* **8**, e2844 <https://doi.org/10.1371/journal.pntd.0002844>
- 11 Wyllie, S., Foth, B.J., Kelner, A., Sokolova, A.Y., Berriman, M. and Fairlamb, A.H. (2016) Nitroheterocyclic drug resistance mechanisms in *Trypanosoma brucei*. *J. Antimicrob. Chemother.* **71**, 625–634 <https://doi.org/10.1093/jac/dkv376>
- 12 Sokolova, A.Y., Wyllie, S., Patterson, S., Oza, S.L., Read, K.D. and Fairlamb, A.H. (2010) Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. *Antimicrob. Agents Chemother.* **54**, 2893–2900 <https://doi.org/10.1128/AAC.00332-10>
- 13 Andrade, H.M., Murta, S.M.F., Chapeaurouge, A., Perales, J., Nirdé, P. and Romanha, A.J. (2008) Proteomic analysis of *Trypanosoma cruzi* resistance to benznidazole. *J. Proteome Res.* **7**, 2357–2367 <https://doi.org/10.1021/pr700659m>
- 14 Murta, S.M.F., Krieger, M.A., Montenegro, L.R., Campos, F.F.M., Probst, C.M., Ávila, A.R. et al. (2006) Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in *Trypanosoma cruzi*. *Mol. Biochem. Parasitol.* **146**, 151–162 <https://doi.org/10.1016/j.molbiopara.2005.12.001>
- 15 Trochine, A., Alvarez, G., Corre, S., Faral-Tello, P., Durán, R., Baththyany, C.I. et al. (2014) *Trypanosoma cruzi* chemical proteomics using immobilized benznidazole. *Exp. Parasitol.* **140**, 33–38 <https://doi.org/10.1016/j.exppara.2014.03.013>
- 16 Garavaglia, P.A., Laverrière, M., Cannata, J.J. and García, G.A. (2016) Putative role of the aldo-keto reductase from *Trypanosoma cruzi* in benznidazole metabolism. *Antimicrob. Agents Chemother.* **60**, 2664–2670 <https://doi.org/10.1128/AAC.02185-15>
- 17 Jez, J.M. and Penning, T.M. (2001) The aldo-keto reductase (AKR) superfamily: an update. *Chem. Biol. Interact.* **130–132**, 499–525 [https://doi.org/10.1016/S0009-2797\(00\)00295-7](https://doi.org/10.1016/S0009-2797(00)00295-7)
- 18 Xu, D., Liu, X., Guo, C., and Zhao, J. (2006) Methylglyoxal detoxification by an aldo-keto reductase in the cyanobacterium *Synechococcus* sp. PCC 7002. *Microbiology* **152**, 2013–2021 <https://doi.org/10.1099/mic.0.28870-0>
- 19 Kubata, B.K., Duszynko, M., Kabututu, Z., Rawer, M., Szallies, A., Fujimori, K. et al. (2000) Identification of a novel prostaglandin F<sub>2a</sub> synthase in *Trypanosoma brucei*. *J. Exp. Med.* **192**, 1327–1338 <https://doi.org/10.1084/jem.192.9.1327>
- 20 Kabututu, Z., Martin, S.K., Nozaki, T., Kawazu, S.-i., Okada, T., Munday, C.J. et al. (2003) Prostaglandin production from arachidonic acid and evidence for a 9,11-endoperoxide prostaglandin H<sub>2</sub> reductase in *Leishmania*. *Int. J. Parasitol.* **33**, 221–228 [https://doi.org/10.1016/S0020-7519\(02\)00254-0](https://doi.org/10.1016/S0020-7519(02)00254-0)
- 21 Garavaglia, P.A., Cannata, J.J.B., Ruiz, A.M., Maugeri, D., Duran, R., Galleano, M. et al. (2010) Identification, cloning and characterization of an aldo-keto reductase from *Trypanosoma cruzi* with quinone oxido-reductase activity. *Mol. Biochem. Parasitol.* **173**, 132–141 <https://doi.org/10.1016/j.molbiopara.2010.05.019>
- 22 Studier, F.W. (2005) Protein production by auto-induction in high-density shaking cultures. *Protein Exp. Purif.* **41**, 207–234 <https://doi.org/10.1016/j.pep.2005.01.016>
- 23 Young, H.D. (1962) *Statistical Treatment of Experimental Data*, McGraw-Hill, New York
- 24 Hunter, K.J., Le Quesne, S.A. and Fairlamb, A.H. (1994) Identification and biosynthesis of N<sup>1</sup>,N<sup>9</sup>-bis(glutathionyl)aminopropylcadaverine (homotrypanothione) in *Trypanosoma cruzi*. *Eur. J. Biochem.* **226**, 1019–1027 <https://doi.org/10.1111/j.1432-1033.1994.t01-1-01019.x>
- 25 Greig, N., Wyllie, S., Patterson, S. and Fairlamb, A.H. (2009) A comparative study of methylglyoxal metabolism in trypanosomatids. *FEBS J.* **276**, 376–386 <https://doi.org/10.1111/j.1742-4658.2008.06788.x>
- 26 Goyard, S., Segawa, H., Gordon, J., Showalter, M., Duncan, R., Turco, S.J. et al. (2003) An *in vitro* system for developmental and genetic studies of *Leishmania donovani* phosphoglycans. *Mol. Biochem. Parasitol.* **130**, 31–42 [https://doi.org/10.1016/S0166-6851\(03\)00142-7](https://doi.org/10.1016/S0166-6851(03)00142-7)
- 27 Moen, S.O., Fairman, J.W., Barnes, S.R., Sullivan, A., Nakazawa-Hewitt, S., Van Voorhis, W.C. et al. (2015) Structures of prostaglandin F synthase from the protozoa *Leishmania major* and *Trypanosoma cruzi* with NADP. *Acta Crystallogr., Sect. F: Struct. Biol. Commun.* **71**, 609–614 <https://doi.org/10.1107/S2053233X15006883>
- 28 Patterson, S., Wyllie, S., Stojanovski, L., Perry, M.R., Simeons, F.R.C., Norval, S. et al. (2013) The R enantiomer of the anti-tubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis. *Antimicrob. Agents Chemother.* **57**, 4699–4706 <https://doi.org/10.1128/AAC.00722-13>
- 29 Wyllie, S. and Fairlamb, A.H. (2011) Methylglyoxal metabolism in trypanosomes and leishmania. *Semin. Cell Dev. Biol.* **22**, 271–277 <https://doi.org/10.1016/j.semcdb.2011.02.001>
- 30 Kilunga, K.B., Inoue, T., Okano, Y., Kabututu, Z., Martin, S.K., Lazarus, M. et al. (2005) Structural and mutational analysis of *Trypanosoma brucei* prostaglandin H<sub>2</sub> reductase provides insight into the catalytic mechanism of aldo-ketoreductases. *J. Biol. Chem.* **280**, 26371–26382 <https://doi.org/10.1074/jbc.M413884200>

- 31 Rath, J., Gowri, V. S., Chauhan, S. C., Padmanabhan, P. K., Srinivasan, N. and Madhubala, R. (2009) A glutathione-specific aldose reductase of *Leishmania donovani* and its potential implications for methylglyoxal detoxification pathway. *Gene* **429**, 1–9
- 32 Kubata, B.K., Kabututu, Z., Nozaki, T., Munday, C.J., Fukuzumi, S., Ohkubo, K. et al. (2002) A key role for old yellow enzyme in the metabolism of drugs by *Trypanosoma cruzi*. *J. Exp. Med.* **196**, 1241–1252 <https://doi.org/10.1084/jem.20020885>
- 33 Hamberg, M. and Samuelsson, B. (1973) Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. *Proc. Natl Acad. Sci. U.S.A.* **70**, 899–903 <https://doi.org/10.1073/pnas.70.3.899>
- 34 Milne, G.L., Yin, H., Brooks, J.D., Sanchez, S., Jackson, R.L. and Morrow, J.D. (2007) Quantification of F<sub>2</sub>-isoprostanes in biological fluids and tissues as a measure of oxidant stress. *Methods Enzymol.* **433**, 113–126 [https://doi.org/10.1016/S0076-6879\(07\)33006-1](https://doi.org/10.1016/S0076-6879(07)33006-1)
- 35 Morrow, J.D., Awad, J.A., Boss, H.J., Blair, I.A. and Roberts, L.J. (1992) Non-cyclooxygenase-derived prostanoids (F<sub>2</sub>-isoprostanes) are formed *in situ* on phospholipids. *Proc. Natl Acad. Sci. U.S.A.* **89**, 10721–10725 <https://doi.org/10.1073/pnas.89.22.10721>
- 36 Roberts, L.J. and Milne, G.L. (2009) Isoprostanes. *J. Lipid Res.* **50**(Suppl), S219–S223 <https://doi.org/10.1194/jlr.R800037-JLR200>
- 37 Davies, S.S. and Guo, L. (2014) Lipid peroxidation generates biologically active phospholipids including oxidatively N-modified phospholipids. *Chem. Phys. Lipids* **181**, 1–33 <https://doi.org/10.1016/j.chemphyslip.2014.03.002>
- 38 Milne, G.L., Dai, Q. and Roberts, L.J. (2015) The isoprostanes—25 years later. *Biochim. Biophys. Acta, Mol. Cell Biol. Lipids* **1851**, 433–445 <https://doi.org/10.1016/j.bbalip.2014.10.007>
- 39 Li, H., Lawson, J.A., Reilly, M., Adiyaman, M., Hwang, S.-W., Rokach, J. et al. (1999) Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F<sub>2</sub>-isoprostanes in human urine. *Proc. Natl Acad. Sci. U.S.A.* **96**, 13381–13386 <https://doi.org/10.1073/pnas.96.23.13381>
- 40 Kabututu, Z., Martin, S.K., Nozaki, T., Kawazu, S., Okada, T., Munday, C.J. et al. (2002) Prostaglandin production from arachidonic acid and evidence for a 9,11-endoperoxide prostaglandin H2 reductase in *Leishmania*. *Int. J. Parasitol.* **32**, 1693–1700 [https://doi.org/10.1016/S0020-7519\(02\)00160-1](https://doi.org/10.1016/S0020-7519(02)00160-1)
- 41 Wermuth, B. (1981) Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase. *J. Biol. Chem.* **256**, 1206–1213 PMID:7005231
- 42 Fersht, A.R. (1974) Catalysis, binding and enzyme-substrate complementarity. *Proc. R. Soc. Lond. B Biol. Sci.* **187**, 397–407 <https://doi.org/10.1098/rspb.1974.0084>
- 43 Copeland, R.A. (2005) Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists John Wiley & Sons, Hoboken, p. 77
- 44 Rabbani, N. and Thornalley, P.J. (2014) Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples. *Nat. Protoc.* **9**, 1969–1979 <https://doi.org/10.1038/nprot.2014.129>
- 45 Inoue, Y., Rhee, H.-i., Watanabe, K., Murata, K. and Kimura, A. (1988) Metabolism of 2-oxoaldehyde in mold. Purification and characterization of two methylglyoxal reductases from *Aspergillus niger*. *Eur. J. Biochem.* **171**, 213–218 <https://doi.org/10.1111/j.1432-1033.1988.tb13778.x>
- 46 Murata, K., Fukuda, Y., Simosaka, M., Watanabe, K., Saikusa, T. and Kimura, A. (1985) Metabolism of 2-oxoaldehyde in yeasts. Purification and characterization of NADPH-dependent methylglyoxal-reducing enzyme from *Saccharomyces cerevisiae*. *Eur. J. Biochem.* **151**, 631–636 <https://doi.org/10.1111/j.1432-1033.1985.tb09151.x>
- 47 Akita, H., Watanabe, M., Suzuki, T., Nakashima, N. and Hoshino, T. (2015) Molecular cloning and characterization of two YGL039w genes encoding broad specificity NADPH-dependent aldehyde reductases from *Kluyveromyces marxianus* strain DMB1. *FEMS Microbiol. Lett.* **362**, fmv116 <https://doi.org/10.1093/femsle/fmv116>
- 48 Thornalley, P.J. (1996) Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification — a role in pathogenesis and antiproliferative chemotherapy. *Gen. Pharmacol.* **27**, 565–573 [https://doi.org/10.1016/0306-3623\(95\)02054-3](https://doi.org/10.1016/0306-3623(95)02054-3)
- 49 Chakraborty, S., Karmakar, K. and Chakravorty, D. (2014) Cells producing their own nemesis: understanding methylglyoxal metabolism. *IUBMB. Life* **66**, 667–678 <https://doi.org/10.1002/iub.1324>
- 50 Opperdoes, F.R. (1984) Localization of the initial steps in alkoxyphospholipid biosynthesis in glycosomes (microbodies) of *Trypanosoma brucei*. *FEBS Lett.* **169**, 35–39 [https://doi.org/10.1016/0014-5793\(84\)80284-7](https://doi.org/10.1016/0014-5793(84)80284-7)
- 51 Güther, M.L.S., Urbaniak, M.D., Tavendale, A., Prescott, A. and Ferguson, M.A.J. (2014) High-confidence glycosome proteome for procyclic form *Trypanosoma brucei* by epitope-tag organelle enrichment and SILAC proteomics. *J. Proteome Res.* **13**, 2796–2806 <https://doi.org/10.1021/pr401209w>
- 52 Jamdhade, M.D., Pawar, H., Chavan, S., Sathe, G., Umasankar, P.K., Mahale, K.N. et al. (2015) Comprehensive proteomics analysis of glycosomes from *Leishmania donovani*. *OMICS* **19**, 157–170 <https://doi.org/10.1089/omi.2014.0163>
- 53 Fairlamb, A.H. and Opperdoes, F. R. (1986) Carbohydrate metabolism in African trypanosomes, with special reference to the glycosome In *Carbohydrate Metabolism in Cultured Cells* (Morgan, M.J., ed.), pp. 183–224, Plenum Publishing Corporation, New York
- 54 Panicucci, R. and McClelland, R.A. (1989) 4,5-Dihydro-4,5-dihydroxyimidazoles as products of the reduction of 2-nitroimidazoles. HPLC assay and demonstration of equilibrium transfer of glyoxal to guanine. *Can. J. Chem.* **67**, 2128–2135 <https://doi.org/10.1139/v89-331>
- 55 Kasai, H., Iwamoto-Tanaka, N. and Fukada, S. (1998) DNA modifications by the mutagen glyoxal: adduction to G and C, deamination of C and GC and GA cross-linking. *Carcinogenesis* **19**, 1459–1465 <https://doi.org/10.1093/carcin/19.8.1459>
- 56 Morrow, J.D., Harris, T.M. and Roberts, L.J. (1990) Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. *Anal. Biochem.* **184**, 1–10 [https://doi.org/10.1016/0003-2697\(90\)90002-Q](https://doi.org/10.1016/0003-2697(90)90002-Q)
- 57 Livore, V.I., Tripodi, K.E.J. and Uttaro, A.D. (2007) Elongation of polyunsaturated fatty acids in trypanosomatids. *FEBS J.* **274**, 264–274 <https://doi.org/10.1111/j.1742-4658.2006.05581.x>
- 58 Uttaro, A.D. (2014) Acquisition and biosynthesis of saturated and unsaturated fatty acids by trypanosomatids. *Mol. Biochem. Parasitol.* **196**, 61–70 <https://doi.org/10.1016/j.molbiopara.2014.04.001>
- 59 Toledo, D.A.M., Roque, N.R., Teixeira, L., Milán-Garcés, E.A., Carneiro, A.B., Almeida, M.R. et al. (2016) Lipid body organelles within the parasite *Trypanosoma cruzi*: a role for intracellular arachidonic acid metabolism. *J. Parasitol. Res.* **11**, e0160433 <https://doi.org/10.1371/journal.pone.0160433>
- 60 Ridgley, E.L. and Ruben, L. (2001) Phospholipase from *Trypanosoma brucei* releases arachidonic acid by sequential sn-1, sn-2 deacylation of phospholipids. *Mol. Biochem. Parasitol.* **114**, 29–40 [https://doi.org/10.1016/S0166-6851\(01\)00234-1](https://doi.org/10.1016/S0166-6851(01)00234-1)
- 61 Catisti, R., Uyemura, S.A., Docampo, R. and Vercesi, A.E. (2000) Calcium mobilization by arachidonic acid in trypanosomatids. *Mol. Biochem. Parasitol.* **105**, 261–271 [https://doi.org/10.1016/S0166-6851\(99\)00186-3](https://doi.org/10.1016/S0166-6851(99)00186-3)

- 62 Ujihara, M., Urade, Y., Eguchi, N., Hayashi, H., Ikai, K. and Hayaishi, O. (1988) Prostaglandin D2 formation and characterization of its synthetases in various tissues of adult rats. *Arch. Biochem. Biophys.* **260**, 521–531 [https://doi.org/10.1016/0003-9861\(88\)90477-8](https://doi.org/10.1016/0003-9861(88)90477-8)
- 63 Ashton, A.W., Mukherjee, S., Nagaiyothi, F.N.U., Huang, H., Braunstein, V.L., Desruisseaux, M.S. et al. (2007) Thromboxane A<sub>2</sub> is a key regulator of pathogenesis during *Trypanosoma cruzi* infection. *J. Exp. Med.* **204**, 929–940 <https://doi.org/10.1084/jem.20062432>
- 64 Morrow, J.D., Awad, J.A., Wu, A., Zackert, W.E., Daniel, V.C. and Roberts, L.J. (1996) Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) *in vivo*. *J. Biol. Chem.* **271**, 23185–23190 <https://doi.org/10.1074/jbc.271.38.23185>
- 65 Turrens, J.F. (2004) Oxidative stress and antioxidant defenses: a target for the treatment of diseases caused by parasitic protozoa. *Mol. Aspects Med.* **25**, 211–220 <https://doi.org/10.1016/j.mam.2004.02.021>
- 66 Mauël, J. (1996) Intracellular survival of protozoan parasites with special reference to *Leishmania* spp., *Toxoplasma gondii* and *Trypanosoma cruzi*. *Adv. Parasitol.* **38**, 1–51 [https://doi.org/10.1016/S0065-308X\(08\)60032-9](https://doi.org/10.1016/S0065-308X(08)60032-9)
- 67 Roberts, L.J., Brame, C.J., Chen, Y. and Morrow, J.D. (1999) Novel eicosanoids. Isoprostanes and related compounds. *Methods Mol. Biol.* **120**, 257–285 <https://doi.org/10.1385/1-59259-263-5:257>